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Background: Symptoms such as medically unexplained vaginal discharge (MUVD) are common and bothersome,
leading to potentially unnecessary use of resources.
Methods: A community-based individually randomized controlled trial to assess the effectiveness of a relatively
simple, culturally appropriate multi-component intervention on reducing reported MUVD, among women suffering
from low-moderate levels of common mental distress. The setting was a socio-economically deprived, informal
settlement in the southern suburbs of Beirut, Lebanon. The intervention comprised up to 12 group sessions
implemented over a six-week period, each divided into a psychosocial and a relaxation exercise component. The
primary outcome was self-reported MUVD, which was defined as a complaint of vaginal discharge upon ruling out
reproductive tract infections (RTIs), through lab analysis. Anxiety and/or depression symptoms were the secondary
outcomes for this trial. These were assessed using an Arabic validated version of the Hopkins Symptoms
Checklist-25 (HSCL-25). Assessments were done at baseline and six months using face-to face interviews, pelvic
examinations and laboratory tests. Women were randomized into either intervention or control group. Blinding on
the intervention status was not possible for both logistic and ethical reasons, especially as knowledge of
involvement in the intervention was integral to its delivery. Intent to treat analysis was used.
Results: Of 75 women randomized to the intervention, 48% reported MUVD at 6 months compared with 63% of
73 in the control group (difference of -15%, 95% confidence interval (CI) -31%, 0%, p=0.067). Adjustments for
baseline imbalances and any factors relating to consent had no appreciable effect on these results. The risk of
MUVD was reduced in absolute terms by 2.4% for each intervention session attended (95% CI -4.9%, 0.0%, p=0.049).
While there was also marginal evidence of a beneficial effect on anxiety, there was no evidence of mediation of the
effect on MUVD through measures of common mental disorders.
Conclusion: This study confirms that MUVD is an important public health problem. While the benefits of this
intervention may appear modest, the intervention offers an opportunity for women to enhance their
problem-solving skills as well as use physical relaxation techniques that can help them deal with stressful in their
lives. Further research is needed in a variety of contexts, for different populations and preferably involving larger
randomized trials of such an intervention.
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Unexplained somatic symptoms are a frequent reason
for consulting health professionals. Repeated consulta-
tions and potentially unnecessary and often expensive
diagnostic procedures add to the burden of these com-
plaints [1]. Common symptoms for which there is no
evident medical explanation are: pain in the limbs, dys-
pnea, headache, back pain, coughing, and vaginal
discharge.
In many parts of the world, vaginal discharge is among
the most commonly reported and bothersome com-
plaints by women in their reproductive years [2-4]. In
Muslim communities, vaginal discharge is considered
troublesome because it affects the woman’s prayer
requirements to be “clean” [5]. Vaginal discharge can be
a consequence of reproductive tract infections (RTIs)
[6-9]; but this is not always the case [10,11]. For in-
stance, in a community-based study in Egypt, 77% of
interviewed women reported abnormal vaginal discharge
in the preceding three months, among whom only 52%
had a confirmed RTI [8].
From the Urban Health Survey in Lebanon, 38% of
ever-married women aged 15-59 years in Hay el Sellom
complained of vaginal discharge, of whom 71% reported
being ‘bothered’ by the complaint. Of those reporting
vaginal discharge, 64% had consulted a health provider
or planned to do so, of whom only a minority had RTIs
[7]. Another similar Lebanese study found 24.5% of the
women reporting vaginal discharge, only 9.3% of whom
actually suffered from RTIs [12]. Hence, this poses the
following inquiry: Could Medically unexplained vaginal
discharge (MUVD) be explained by common mental dis-
orders (CMDs) such as anxiety and depression? [9]. Sev-
eral studies have observed an association between
anxiety and/or depression with medically unexplained
gynaecological symptoms such as pelvic pain and abnor-
mal vaginal discharge [6,9,13-16]. Many studies have
shown that this association remains after adjusting for
relevant risk factors and/or RTIs [17,18].
Available research focuses on intervention strategies to
improve CMDs, and it remains to be demonstrated
whether such strategies improve MUVD. This paper
describes the results of a community-based randomized
controlled trial to decrease the burden of MUVD byfocusing on CMDs. The trial aimed to assess the effect-
iveness of a relatively simple, culturally appropriate
multi-component intervention on reducing reported
MUVD, among women suffering from low-moderate
levels of common mental distress.
Methods
Design
An individually randomized controlled trial (RCT) [19].
Setting
Hay el Sellom in the southern suburbs of Beirut, Lebanon,
an informal settlement of approximately 150,000 mainly
Lebanese Shiites, with low levels of basic health care
services, education and physical infrastructure [20].
Recruitment
A total of 33 schools, three large factories, 14 gynaeco-
logical clinics and eight satellite network providers facili-
tated recruitment over six weeks (1 April to 15 May
2009), administering a questionnaire to all potentially
eligible women. This questionnaire comprised symptoms
of vaginal discharge, general inclusion/exclusion criteria
and (for those reporting vaginal discharge) items relating
to common mental disorders (CMDs). To rule out RTIs,
women reporting vaginal discharge were referred for la-
boratory tests and a pelvic examination conducted by fe-
male gynaecologists trained in the protocol. Swab
specimens were transported and analyzed by a trained
technician from the American University of Beirut la-
boratory. The following lab tests were used to rule out
each of the five different RTIs of interest to this trial
(coupled with their respective sensitivities and specifici-
ties): COBAS AMPLICOR Nisseria gonorrhea/Chlamydia
trachomatis Test” (Roche Molecular Diagnostics) was
used for qualitative in vitro detection of N. gonorrhea
(sensitivity 96.4%, specificity 97.9%) and C. trachomatis
(sensitivity 93.4%, specificity 96.7%). “Tv latex” and “Can-
dida Latex” (Kalon Biological Ltd) were used for T. vagi-
nalis (sensitivity 95%, specificity 99%) and candidiasis
(sensitivity 80%, specificity 100%) detection. Nugent Score
technique (sensitivity 87.5%, specificity 95%) was followed
for the assessing of bacterial vaginosis [21-25].
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18-49; reporting symptoms of vaginal discharge; low to
moderate scores on the Hopkins Symptom Checklist-25
(HSCL-25) (ranging between 2.1-3.3 for the depression
sub-scale and 2.0-3.2 for the anxiety sub-scale); signed
informed consent. Exclusion criteria were: pregnant or
less than 8 weeks postpartum; post-menopause or hys-
terectomy; reporting treatment for severe mental illness;
positive RTI test (bacterial vaginosis, trichomoniasis,
fungal infection, chlamydia, and gonorrhoea).
Two different consent forms were used. The first was
used during the recruitment phase to obtain permission
to check for the inclusion/exclusion criteria including
the pelvic examination and the lab tests. This consent
form was read to the woman by an interviewer in front
of a witness prior to the pelvic examination. The second
consent was obtained by trained trial staff from women
who were eligible to participate in the trial. It ensured
that women understood the trial procedures and reasons
behind their eligibility.
Randomization, concealment of allocation and blinding
Randomization was performed using a computer-
generated allocation schedule, produced by an individual
not involved in recruitment. The original intention was
that the baseline measures and consent were to be
obtained before allocation was determined remotely (by
telephone) and then revealed to the woman. In the
event, logistical constraints at the recruitment centres
meant that remote allocation was not feasible and allo-
cation was performed using the computerized system as
planned, but in the field rather than remotely. An unin-
tended consequence of this change in procedure was
that the women were informed of their allocation into
either the intervention or the control arm before they
gave final written consent. As will be detailed in the ana-
lysis section, this departure from protocol necessitates
particularly extensive comparison of characteristics of
the (consenting) women at baseline, with suitable con-
trol for any differential selection across the trial arms.
Blinding of allocation after randomisation was not feas-
ible given the nature of the intervention.
Intervention
This consisted of 12 group sessions implemented over a
six-week period using local facilities, given only to the
intervention arm of the trial. Each session was divided
into two parts (delivered in an order determined by
practical circumstances): a psychosocial component and
a relaxation exercise component.
The psychosocial component lasted approximately
75 minutes and was delivered by five Masters level clin-
ical psychologists, assisted by five social workers as
co-moderators. These sessions were divided into directedand semi-structured social support discussion sessions,
incorporating problem-solving skills building as well as
venting. Once a group was formed its members remained
in the same group throughout. Those delivering the
intervention received two days of training from a senior
clinical psychologist, and were provided with a manual
describing each session in detail.
The relaxation and exercise component involved
30 minutes sessions run by physical trainers. The exer-
cises were introduced gradually. They included teaching
women how to engage in visual guided imagery exercises
on their own, coupled with stretching and progressive
muscle relaxation. Each session started with a summary
of the previous session, a review of what was being prac-
ticed at home, followed by introducing an additional
technique. A manual was also developed by a physical
fitness specialist who supervised and trained the physical
trainers over two days. A brief pamphlet was given to
participants describing the components of each session.
The control group was a treat later group, which
received the intervention after the study was completed.
Those women in the control group were divided into
groups and offered the same intervention protocol as in
the trial, using the same facilitators and locale. During
the trial controls received usual care but they were fol-
lowed up by two clinical psychologists (as requested by
the IRB), over the phone, every two weeks by adminis-
tering the HSCL-25 -in order to ensure that their CMD
status did not regress.
Outcome assessments
Data collection took place at baseline, 1.5 months and
six months using face-to-face interviews conducted by
trained interviewers. The primary outcome was MUVD
at six months. A woman was considered to have MUVD
if she reported a complaint of vaginal discharge as
assessed by the question: “are you complaining currently
from vaginal discharge?” and was concurrently not suf-
fering from any RTIs, as confirmed by pelvic exam and
laboratory tests. Further questions asked whether or not
they were bothered by MUVD, to indicate the colour,
odour, thickness, consistency and frequency of the
discharge.
Secondary outcomes included common mental dis-
order (CMD) as assessed by the Hopkins Symptom
Checklist 25 (HSCL-25). This is known to have good
psychometric properties [26,27] but was subjected to
further field-testing in Lebanon prior to the trial. From
these investigations, cut-off values of 2.10 and 2.00 on
the HSCL-25 were determined for depression and anx-
iety respectively [28].
The third secondary outcome was somatisation, using
the Scale for Assessment of Somatic Symptoms. The
main purpose of the 1.5 months follow-up was to
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Allowing for 10% attrition, 80-102 women in each group
would provide 80-90% power to detect a difference of 20
percentage points (10% vs. 30%) in the primary outcome
of reported MUVD at 6 months, using a 2-sided 5% sig-
nificance level. There is no previous study to inform this
effect size directly, but differences in CMD recovery
rates of up to 40% between usual care and active inter-
ventions for CMD have been found [8,9]. A 20 percent-
age point difference in MUVD was chosen because in
our judgement such a difference would be clinically
worthwhile and the effects on CMD suggest that such a
difference is plausible.
Data analysis
Using SPSS version 16 and Stata version 11 the trial was
analyzed and reported in accordance with CONSORT
guidelines. Descriptive statistics were used to compare
the two groups as randomized on 14 socio-demographic
and clinical variables. Since (final) consent was obtained
after randomization, those consenting and not consent-
ing were compared on the basis of the same 14
characteristics.
The primary analysis involved calculating the differ-
ence in the percentages of women with MUVD at
6 months between the groups as randomized (including
the 95% confidence interval (CI) and the number-
needed-to-treat. For interpretation alongside secondary
analyses the primary comparison was repeated using lo-
gistic regression to obtain the odds ratio, its 95% CI and
p-value. The main secondary analyses involved multi-
variable logistic regression to adjust for baseline imbal-
ances across the groups of (randomized and consented)
women and those characteristics associated with con-
sent. The regression analyses were then repeated using
multiple regression models for the three secondary out-
comes. All regression analyses were performed before
and after imputing missing outcome data using multiple
imputations by chained equations [29].
Additional secondary analyses for explanatory pur-
poses involved investigating clustering effects of the
intervention groups women were assigned to, using
mixed effects regression for the primary outcome.
Potential mediators were investigated by adding (sep-
arately) changes in HSCL-25 Anxiety and Depression
sub-scales and the somatisation scale scores to the
original regression models with the primary outcome.
Adherence effects were investigated using instrumental
variables regression with a linear term for the number
of sessions attended. These were run both on the riskdifference scale for the MUVD outcome and following
a probit transformation. The results for both sets of
models were very similar and only the former are
reported. The final set of secondary analyses involved
adding appropriate interaction terms to the regression
models for the primary and secondary outcomes to inves-
tigate differential effects of the intervention according to
age and baseline HSCL-25 scores, all as continuous
variables.
Results
A total of 1015 women were screened over six weeks of
recruitment (Figure 1). Among these, 736 (73%) reported
having experienced vaginal discharge of whom 491
(67%) had symptoms of CMD (low or moderate). After
excluding those testing positive for any RTI (medically
explained vaginal discharge) and the 97 women who
were not tested for RTIs, 271 were randomized
(Figure 1). As described above, consent to participate in
the trial was then sought; 32 (24%) and 43 (31%) of
women in the intervention and control groups re-
spectively refused to take part at this point. This left
99 intervention and 97 control women randomized and
subsequently consenting, of whom 10 and 16 were lost
to follow-up respectively. Of the remaining women,
14/89 and 8/81 tested positive for RTIs in the 6-month
assessment for the intervention and control groups re-
spectively, resulting in 75 (76% of those randomized and
consenting) and 73 (75% of 97) women on whom the
primary outcome was known.
Socio-demographic characteristics were similar across
the study arms at baseline (Table 1), although those in
the intervention arm were slightly more likely to be
employed in skilled labour and have husbands with
lower educational levels. Potentially more important are
the higher proportions of consenting women in the
intervention arm reporting bothersomeness, wetting
underpants and reasons other than infection for their
vaginal discharge (Table 1). While this may raise con-
cerns about differential consent across the arms in terms
of perceived problems due to vaginal discharge, there
are no differences between the arms in baseline mental
health scores. However, overall the 196 women who con-
sented were more likely than the 75 women who refused
consent after randomization to have never worked, to at-
tribute their vaginal discharge to stress and/or emotional
causes, and less likely to report wetting underpants due
to vaginal discharge (data not shown). Moreover, those
consenting had higher HSCL-25 scores for anxiety and
depression (both worse by about a third of a standard
deviation). In addition, at baseline, women in both arms
did not differ in terms of IUD use, oral contraceptive
use, or seeking medical consultation for their condition
(6.5% in the intervention arm vs 10.5%; 11.8% in the
Figure 1 Participant flow (VD – vaginal discharge; CMD – common mental disorders; RTI – reproductive tract infection;
MUVD – medically unexplained VD).
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intervention arm vs 40.4% in the control arm, respect-
ively). These observations indicate that the following
variables warrant further consideration in the analysis:
women’s type of work; husband’s educational level; both-
ersomeness, wetting underpants and perceived reasons
for vaginal discharge; HSCL-25 anxiety and depression
scores.
At six months, a smaller proportion in the interven-
tion arm reported MUVD than in the control arm
(Table 2). The absolute difference and the (unadjusted)
odds ratio were sizeable, but there was only weak evi-
dence of a difference beyond chance (p=0.067). From
the unadjusted figures the number-needed-to-treat was
just under 7. Adjustment for the variables related toconsent and/or exhibiting any suggestion of baseline im-
balance had only a minimal impact on the odds ratio
and confidence interval. Likewise, imputing missing
values had very little effect on the results – for instance,
the unadjusted results changed to an odds ratio of 0.56
(95% CI 0.29, 1.09), p=0.086. For the three secondary
outcomes at 6 months there was also only weak evi-
dence of a (beneficial) effect of the intervention (Table 3),
predominantly in anxiety score. Again, imputing missing
outcome data had no appreciable effect on these results
(data not shown).
Consenting women in the intervention arm were
assigned to one of ten groups (median of 9 women per
group; all but two in the range 7-12). Adjusting for clus-
tering by intervention group had very little impact on
Table 1 Baseline characteristics across the arms of the
trial amongst women who consented to participate





Age in years Mean (sd) 34.3 (6.3) 34.9 (7.3)
Education
Illiterate/Less than Elementary 25 (25.3%) 30 (30.9%)
Elementary 41 (41.4%) 40 (41.2%)
High school 20 (20.2%) 14 (14.4%)
Vocational 8 (8.1%) 8 (8.2%)
College/University 5 (5.1%) 5 (5.2%)
Type of work of the woman
Never worked 59 (59.6%) 62 (63.9%)
Unskilled 11 (11.1%) 12 (12.4%)
Skilled labour 16 (16.2%) 8 (8.2%)
Professional 13 (13.1%) 15 (15.5%)
Education of husband
Illiterate/Less than Elementary 40 (40.4%) 31 (32.0%)
Elementary 32 (32.3%) 42 (43.3%)
High school or above 27 (27.3%) 24 (24.7%)
Work status of husband
Not currently working 2 (2.0%) 4 (4.1%)
Currently works 97 (98.0%) 93 (95.9%)
Type of work of husband
Unskilled 24 (24.2%) 21 (21.6%)
Skilled labour 20 (20.2%) 16 (16.5%)
Professional 2 (2.0%) 2 (2.1%)
Company employees 26 (26.3%) 33 (34.0%)
Army/security 6 (6.1%) 6 (6.2%)
Unspecified 21 (21.2%) 19 (19.6%)
Annual family income in
1,000 LL (1US$=1,500LL)
Median(IQR) 800 (400) 750 (400)
Bothered by VD 76 (76.8%) 67 (69.8%)
Report wetting underpants due to VD 80 (81.6%) 63 (66.3%)
Woman attributes VD to:
Stress/Emotional 14 (14.4%) 7 (7.3%)
Infection 31 (32.0%) 43 (44.8%)
Other 19 (19.6%) 12 (12.5%)
Do not know 33 (34.0%) 34 (35.4%)
Satisfied living in this area 64 (65.3%) 59 (60.8%)
Intend to leave the area 55 (56.1%) 57 (58.8%)
HSCL-25 Anxiety score Mean (sd) 2.5 (0.4) 2.4 (0.4)
HSCL-25 Depression score Mean (sd) 2.5 (0.4) 2.4 (0.4)
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those in Table 3. From Table 4, there was no evidence of
mediating effects for the primary outcome in terms of
anxiety, depression or somatisation scores. In respect of
adherence, none of those in the control group receivedany of the intervention prior to the primary outcome
being ascertained, while 49/75 (65%) women in the
intervention group attended at least six sessions. From
the instrumental variables regression analyses, the risk of
MUVD was reduced in absolute terms by 2.4 percentage
points for each session attended (95% CI -4.9%, 0.0%,
p=0.049).
Introducing interaction terms between randomization
group and age, HSCL-25 Anxiety and Depression scores
provided no evidence of differential effects of the inter-




This is the first community-based randomized trial on
MUVD using a group multi-component intervention.
There was marginal evidence of a beneficial effect of the
intervention in terms of reducing MUVD and anxiety at
six months, but with no evidence that the former was
mediated by the latter. The confidence intervals rule out
any important deleterious effects of the intervention but
the precision attained leaves equivocal results as to
whether there is a clinically important benefit from the
intervention. A reduction of 15 percentage points in the
proportion reporting MUVD at 6 months in favour of
the intervention is close to the target difference of 20,
and the ‘upper’ confidence limit for this difference
reaches 30 percentage points. If there were to be a re-
duction in risk of 2 percentage points per session
attended in a population where this condition is highly
prevalent then there is the potential for substantial
population benefits.
Limitations and strengths
The logistical difficulties in recruitment meant that
randomization was not fully concealed, and this could
explain some of the observed disparities across the arms
at baseline. There is clear evidence, however, to suggest
that these small imbalances did not impact on the
results and conclusions. The imprecision in the estimate
of effectiveness partly reflects the original target differ-
ence, which was large for such an intervention with this
degree of intensity and duration. Furthermore, the pro-
portions with MUVD at follow-up were larger (and
closer to 50%) than anticipated. Focusing the trial on a
population with low to moderate levels of CMD may
have limited the extent to which the intervention could
reduce psychological distress and the primary MUVD
outcome. Most pragmatic trials such as this with usual
care as control arm might be affected by a Hawthorne
or 'attention' effect. Nonetheless adding an 'attention
control group' would have made this trial less pragmatic.
Finally we have used self-reported questionnaires rather
Table 2 Differences in reported Medically Unexplained Vaginal Discharge (MUVD) at 6 months across groups
Intervention Control % Difference (95% CI) OR (95% CI) p-value
Unadjusteda 36/75 (48.0%) 46/73 (63.0%) -15.0% (-30.8%, 0.1%) 0.54 (0.28, 1.05) 0.067
Adjustedb 0.46 (0.22, 0.98) 0.045
Adjustedc 0.46 (0.21, 0.98) 0.043
a primary intention-to-treat (ITT) analysis based on the 148 women with known primary outcome status.
b ITT adjusted for women’s work type, husband’s education, VD bothersomeness, wet underpants, reason for VD (n=145).
c ITT adjusted for women’s work type, husband’s education, VD bothersomeness, wet underpants, reason for VD and baseline HSCL-25 Anxiety and Depression
scores (n=145).
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to be used in the clinics unlike the latter which are long
and may require specialist input. This may have intro-
duced some misclassification of cases but most likely
similar across arms so that effect sizes were unlikely to
be affected by this potential problem.
The study strengths include the approach to recruitment,
which was characterized by a wide scale engagement of the
community at all stages – planning, implementation and
evaluation. Study participants reported high levels of sa-
tisfaction and attendance was good [20]. Attrition rates
were low for the study context, and from the results of
the analyses employing multiple imputations there was
very little bias introduced through missing outcome data.
Despite the problems encountered with concealment of
randomization, the results suggest that the primary ana-
lysis could be a reflection of the effectiveness of the
intervention.Relationship with the existing literature
There is evidence from randomized controlled trials that
simple psychological interventions can help to alleviate
CMD, in a variety of settings [30-33]. There is also some
evidence that interventions designed to increase physical
activity can help to alleviate psychological symptoms
[34,35]. There have been attempts to investigate the
effects of interventions designed to reduce medically un-
explained symptoms, but with very limited success [36].
As far as we are aware, the present study is the first to
evaluate the effectiveness of a multi-component inter-
vention of this kind in relation to MUVD, especially in a
developing country and with attention to potential medi-
ation through CMD.Table 3 Unadjusted and adjusted differences in HSCL-25 Anx
months
Difference between meansa (Intervention minus C
HSCL-25 Anxiety -0.16 (-0.32, 0.01)
HSCL-25 Depression -0.09 (-0.24, 0.06)
Somatisation score -0.81 (-4.90, 3.27)
a adjusted for baseline score on the outcome involved.
b adjusted for baseline score, women’s work type, husband’s education, VD bothers
depression scores.Mechanisms of change
The multi-component intervention investigated was
intended to reduce anxiety and depressive symptoms,
and in turn reduce MUVD. The effects of the interven-
tion on these (secondary) outcomes were marginal,
though the fact that results were clearer for anxiety may
indicate that MUVD reflects uncertainty about the
origins of a presumably physical problem. However,
the mediation analyses did not add to understanding
the mechanism involved in any change in MUVD. Since
the intervention was not designed to focus on somatisa-
tion itself, it is less surprising that this neither changed
nor contributed any mediating influence.Implications of the findings
This study confirms that MUVD is an important public
health problem, highly resistant to change – even in the
intervention group; nearly half of the women still had
MUVD after six months. In settings with limited
resources including few trained psychotherapists, as well
as long periods of conflict and instability, the use of this
potentially low cost, acceptable and easy to run group
intervention package is worth considering. While the
benefits of this intervention may appear modest, the
intervention offers an opportunity for women to en-
hance their problem-solving skills as well as apply phys-
ical relaxation techniques that can help them deal more
readily with stress in their lives.
Also it is important to note that due to a portion of
women who refused to participate in the study, it is diffi-
cult to generalize the results to the larger population of
women in Lebanon or in this area since the sample of
women who did not participate may have particulariety, HSCL-25 Depression and somatisation scores at 6
ontrol) (95% CI) p-value Adjusted differenceb (95% CI) p-value
0.06 -0.16 (-0.33, 0.02) 0.08
0.24 -0.10 (-0.27, 0.06) 0.22
0.69 -0.43 (-4.93, 4.07) 0.85
omeness, wet underpants, reason for VD and baseline HSCL-25 anxiety and
Table 4 Assessing the mediating effect of HSCL-25
Anxiety, HSCL-25 Depression and the somatisation scale
scores on the primary analysis of MUVD as the outcome
Possible mediating variable ORa (95% CI) p-value












a OR for MUVD for intervention compared with control adjusting for the
possible mediating variable.
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population.
Further research is still needed in a variety of contexts,
for different populations and preferably involving larger
randomized trials of this intervention (or adaptations of
it). This would enable smaller but potentially important
effect sizes to be estimated with sufficient precision,
which is crucial given the public health implications for
what is a widespread, costly and cumbersome problem
for women in such contexts.
Conclusion
This study confirms that MUVD is an important public
health problem. While the benefits of this intervention
may appear modest, the intervention offers an opportun-
ity for women to enhance their problem-solving skills as
well as use physical relaxation techniques that can help
them deal with stressful in their lives. Further research is
needed in a variety of contexts, for different populations
and preferably involving larger randomized trials of such
an intervention.
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